Noble Financial Has Bearish Forecast for CVKD Q1 Earnings

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Noble Financial cut their Q1 2026 earnings per share (EPS) estimates for Cadrenal Therapeutics in a research note issued to investors on Wednesday, April 1st. Noble Financial analyst R. Leboyer now forecasts that the company will post earnings of ($1.86) per share for the quarter, down from their previous estimate of ($1.33). The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($7.59) per share. Noble Financial also issued estimates for Cadrenal Therapeutics’ Q2 2026 earnings at ($1.95) EPS, Q3 2026 earnings at ($2.10) EPS, Q4 2026 earnings at ($1.85) EPS and FY2026 earnings at ($7.74) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $32.00.

Cadrenal Therapeutics Price Performance

Cadrenal Therapeutics stock opened at $4.70 on Friday. Cadrenal Therapeutics has a 12-month low of $4.21 and a 12-month high of $17.97. The firm’s fifty day moving average is $6.63 and its 200 day moving average is $9.35. The company has a market capitalization of $11.80 million, a PE ratio of -0.70 and a beta of 1.53.

Cadrenal Therapeutics (NASDAQ:CVKD) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.24).

Institutional Trading of Cadrenal Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. DRW Securities LLC bought a new stake in Cadrenal Therapeutics in the fourth quarter worth about $171,000. Geode Capital Management LLC grew its position in shares of Cadrenal Therapeutics by 14.3% during the 4th quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock valued at $98,000 after acquiring an additional 1,818 shares during the period. JPMorgan Chase & Co. bought a new position in shares of Cadrenal Therapeutics during the 3rd quarter valued at approximately $103,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Cadrenal Therapeutics during the 3rd quarter worth approximately $274,000. Hedge funds and other institutional investors own 7.92% of the company’s stock.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.